iDayo Selects MYGN as Low Risk Investment

Call Now
800-993-0005

(^DJI) 0

0S&P 500 (^GSPC) 1318.29

-0.57NASDAQ Composite (^IXIC) 2832.94

-17.18Russell 2000 (^RUT) 759.57

-5.6

iDayo™ Stock Selector: MYGN - Myriad Genetics

iDayo™ 03/17/09: Myriad Genetics (MYGN) - 03/17/09

For the 16 week investment period starting 03/17/09 , the iDayo™ Stock Selector rated Myriad Genetics (MYGN) as "Heavy Accumulation" and selected MYGN as a buy for the investment period, identified as iDayo™ 03/17/09.

Company Profile for "Myriad Genetics (MYGN)": Develops therapeutics by analyzing genes and their mutations in the fields of cancer, Alzheimer`s disease and aids.

Google Finance History for MYGN

iDayo, Inc. (including its marketing professionals and staff), is not a registered Investment Advisor or Broker/Dealer, and does not provide investment advice or recommendations. Subscribers to iDayo™ are advised that the information, opinions, and analysis included in our web sites, on our free Educational Conference Calls, or in any other communication are based in good faith on sources believed to be reliable, but no representation or warranty, expressed or implied, is made as to their accuracy, completeness, or correctness.

Past performance is not necessarily indicative of the future performance of stocks posted. None of these postings, the iDayo™ system rating, nor any other information provided on our web sites, on our free Educational Conference Calls, or in any other communication constitutes a recommendation to buy or sell stocks or any other investment. Investing involves the risk of loss and Subscribers are urged to consult with their own independent financial advisors with respect to any investment.